{"id":"861e675b79eb","type":"article","url":"https://hartvaat.nl/2021/03/09/10-jaarsfollow-up-ees-versus-bms-bij-stemi-examination/","title":"10-jaarsfollow-up EES versus BMS bij STEMI: EXAMINATION","title_en":"10-Year Follow-Up of Patients With Everolimus-Eluting Versus Bare-Metal Stents After ST-Segment Elevation Myocardial Infarction.","category":"algemeen","category_label":"Algemeen","professions":["cardioloog"],"tags":[],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2020.12.059","source_url":"https://doi.org/10.1016/j.jacc.2020.12.059","authors":["Salvatore Brugaletta","Josep Gomez-Lara","Luis Ortega-Paz","Victor Jimenez-Diaz","Marcelo Jimenez","Pilar Jiménez-Quevedo","Roberto Diletti","Vicente Mainar","Gianluca Campo","Antonio Silvestro","Jaume Maristany","Xacobe Flores","Loreto Oyarzabal","Antonio De Miguel-Castro","Andrés Iñiguez","Antonio Serra","Luis Nombela-Franco","Alfonso Ielasi","Maurizio Tespili","Mattie Lenzen","Nieves Gonzalo","Pascual Bordes","Matteo Tebaldi","Simone Biscaglia","Juan Jose Rodriguez-Arias","Soheil Al-Shaibani","Victor Arevalos","Rafael Romaguera","Joan Antoni Gomez-Hospital","Patrick W Serruys","Manel Sabaté"],"significance":7,"published":"2021-03-09","source_date":"2021-03-09","image":"","kennis":[],"congress":"","summary_en":"The 10-year EXAMINATION follow-up confirmed the sustained superiority of everolimus-eluting stents over bare-metal stents in STEMI patients, providing the longest randomized comparison of DES versus BMS in primary PCI.","created":"2026-07-03T10:29:05Z","updated":"2026-07-03T13:28:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"EXAMINATION trial 10-jaarsfollow-up van everolimus-eluting versus bare-metal stents bij STEMI.","abstract_original":"BACKGROUND: Outcomes data for a durable-polymer everolimus-eluting stent (EES) at extended long-term follow-up in patients with ST-segment elevation myocardial infarction (STEMI) are unknown. OBJECTIVES: The aim of this study was to assess the 10-year outcomes of patients enrolled in the EXAMINATION (A Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients With ST-Segment Elevation Myocardial Infarction) trial. METHODS: The EXAMINATION-EXTEND (10-Years Follow-Up of the EXAMINATION Trial) study is an investigator-driven 10-year follow-up of the EXAMINATION trial, which randomly assigned 1,498 patients with STEMI in a 1:1 ratio to receive either EES (n = 751) or bare-metal stents (n = 747). The primary endpoint was a patient-oriented composite endpoint of all-cause death, any myocardial infarction, or any revascularization. Secondary endpoints included a device-oriented composite endpoint of cardiac death, target vessel myocardial infarction, or target lesion revascularization; the individual components of the combined endpoints; and stent thrombosis. RESULTS: Complete 10-year clinical follow-up was obtained in 94.5% of the EES group and 95.9% of the bare-metal stent group. Rates of the patient-oriented composite endpoint and device-oriented composite endpoint were significantly reduced in the EES group (32.4% vs. 38.0% [hazard ratio: 0.81; 95% confidence interval: 0.68 to 0.96; p = 0.013] and 13.6% vs. 18.4% [hazard ratio: 0.72; 95% confidence interval: 0.55 to 0.93; p = 0.012], respectively), driven mainly by target lesion revascularization (5.7% vs. 8.8%; p = 0.018). The rate of definite stent thrombosis was similar in both groups (2.2% vs. 2.5%; p = 0.590). No differences were found between the groups in terms of target lesion revascularization (1.4% vs. 1.3%; p = 0.963) and definite or probable stent thrombosis (0.6% vs. 0.4%; p = 0.703) between 5 and 10 years. CONCLUSIONS: At 10-year follow-up, EES demonstrated confirmed superiority in combined patient- and device-oriented composite endpoints compared with bare-metal stents in patients with STEMI requiring primary percutaneous coronary intervention. Between 5- and 10-year follow-up, a low incidence of adverse cardiovascular events related to device failure was found in both groups. (10-Years Follow-Up of the EXAMINATION Trial; NCT04462315)."}